{"id":13874,"date":"2025-05-22T10:32:46","date_gmt":"2025-05-22T08:32:46","guid":{"rendered":"https:\/\/www.convegnonazionaleaiic.it\/bridging-the-gap-between-innovation-and-clinical-practice-in-the-treatment-of-traumatic-injuries-to-the-osteochondral-tissues-the-luminate-project\/"},"modified":"2025-06-04T14:23:44","modified_gmt":"2025-06-04T12:23:44","slug":"bridging-the-gap-between-innovation-and-clinical-practice-in-the-treatment-of-traumatic-injuries-to-the-osteochondral-tissues-the-luminate-project","status":"publish","type":"post","link":"https:\/\/www.convegnonazionaleaiic.it\/bridging-the-gap-between-innovation-and-clinical-practice-in-the-treatment-of-traumatic-injuries-to-the-osteochondral-tissues-the-luminate-project\/","title":{"rendered":"BRIDGING THE GAP BETWEEN INNOVATION AND CLINICAL PRACTICE IN THE TREATMENT OF TRAUMATIC INJURIES TO THE OSTEOCHONDRAL TISSUES: THE LUMINATE PROJECT"},"content":{"rendered":"
\n
\n

\"\"\"\"<\/p>\n

AFFILIAZIONE<\/span><\/strong><\/p>\n

insideai<\/p>\n


\nAUTORE PRINCIPALE<\/span><\/strong><\/p>\n

PhD Coro Florinda<\/p>\n

VALUTA IL CHALLENGE
\n<\/span><\/strong><\/p>\n

Registrazione obbligatoria. Una valutazione consentita<\/em><\/div>\n
\t\t
\n\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tLogin<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tRegistrazione<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

login avvenuto<\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tLogout<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<\/div>\n
[ratingwidget]<\/div>\n<\/div>\n
\n

<\/a><\/p>\n

GRUPPO DI LAVORO<\/span><\/strong><\/p>\n

PhD Coro Florinda<\/strong> insideai
\nIng. Ravizza Alice<\/strong> insideai
\nPhD Hausner Sebastian<\/strong> university hospital w\u00fcrzburg
\nProf. Pullig Oliver<\/strong> university hospital w\u00fcrzburg
\nProf. Bloemen Veerle<\/strong> ku leuven
\nProf. van Osch Gerjo<\/strong> erasmus mc, university medical center rotterdam
\nPhD Bonatti Amedeo Franco<\/strong> universit\u00e0 di pisa
\nProf. Weinans Harrie<\/strong> university medical centre utrecht
\nProf. Zenobi-Wong Marcy<\/strong> eth zurich
\nProf. Ulrich Inga<\/strong> university of zagreb
\n de Vivans Raphael<\/strong> efmc Prof. Vozzi Giovanni<\/strong> universit\u00e0 di pisa<\/p><\/div>\n

AREA TEMATICA<\/span><\/strong><\/p>\n

Applicazioni innovative di bioingegneria: idee dalle Universit\u00e0<\/div>\n

ABSTRACT<\/span><\/strong><\/p>\n

Traumatic cartilage injuries in diarthrodial joints, such as the knee, affect over 2 million people annually. Despite advances in treatment, many patients develop post-traumatic disabling osteoarthritis highlighting the urgent need for more effective solutions. The LUMINATE project proposes a one-stage, personalized treatment based on the deposition of photoresins filled with patient-derived cells through an AI driven bioprinting unit: Endoflight. The successful clinical translation of LUMINATE relies on a rigorous regulatory strategy to ensure compliance with the Medical Device Regulation (MDR), the Advanced Therapy Medicinal Products (ATMP) Regulation and AI Act: InsideAI srl participates to define such strategy. The LUMINATE bioprinting unit will require CE marking, demonstrating adherence to general safety and performance standards of MDR. The AI software for defect segmentation and material quantification is classified as medical device, requiring compliance with both MDR and AI act. From a qualification standpoint, the bioprinted constructs are regulated as ATMPs under European Medicinal Agency guidelines, due to the incorporation of viable cells aimed at regenerating damaged cartilage. When combined with a non-viable structure that provides structural support, the product is classified as a combination device. To ensure the safety and efficacy of the bioprinted constructs, biocompatibility testing will be necessary together with sterility assurance, and mechanical stability. For the cell-based components, strict GMP compliance is mandatory for cell isolation, expansion, and differentiation protocols, to ensure traceability and consistency. GLP standards will govern preclinical validation, the end point of LUMINATE project, including in vitro studies and large-animal models to evaluate the biological response, integration, and long-term functionality of the implants. To bring a medical device to market, it must undergo safety testing, preclinical trials on animals, and a series of extensive clinical studies, that are out of scope of the project. By including in the design pathway a robust regulatory approach, the LUMINATE project aims to set a new standard in personalized, minimally invasive cartilage repair, bridging the gap between cutting-edge innovation and clinical feasibility while addressing the growing medical and socioeconomic burden of post-traumatic osteoarthritis.<\/div>\n

 <\/p>\n

\n\n